Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Valeant Pharmaceuticals acquires DermaTech
Aliso Viejo, Calif. - Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, marketwatch reports.
Aliso Viejo, Calif.
- Valeant Pharmaceuticals has announced it has acquired DermaTech, an Australian pharmaceutical company focused on dermatology products, for AU$19 million, marketwatch reports.
The transaction will expand Valeant’s specialty pharmaceutical portfolio through the acquisition of key products,according to the company.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
